Now accepting research commissions

Ablation-first research
on Indian listed companies.

Productized deep-dive research for family offices, boutique PMS, independent RIAs, and AMC research desks. 5-year OOS validated methodology. Published negative findings alongside positive.

The research anchor

An 8-month, 5-year OOS ablation study.

We studied Indian mid-cap momentum strategies across a complete 5-year out-of-sample window (2021-2025). The finding that reversed prior consensus: neither volatility-adjustment nor regime-gating adds alpha. The simplest variant — raw momentum — is the only one passing all 8 validation gates.

0.96

OOS Sharpe

2.05

Alpha t-stat

0.63

DSR

8/8

Validation gates

“Do Regime Filters Add Value? An Ablation Study of Volatility-Adjusted Momentum in Indian Mid-Cap Equities.” In submission to arXiv + SSRN · target journals: Pacific-Basin Finance Journal, Journal of Empirical Finance, Quantitative Finance.

What we offer

From research framework to productized deep-dives.

Every report applies the same ablation-first methodology to individual Indian listed companies.

Point-in-time universe

Survivorship-bias-free data. No retrospective selection. Corporate-action adjusted (splits, bonuses, dividends, de-mergers).

Full factor decomposition

Market, size, momentum, value exposures. Distinguishes factor-driven returns from genuine idiosyncratic alpha.

Rigorous validation

Bootstrap CIs, Deflated Sharpe Ratio, Probabilistic Sharpe Ratio, walk-forward testing. Not backtest-flattered.

Ablation appendix

Every finding tested against its own inverse. How robust is the thesis? If it breaks under alternative specifications, we say so — with numbers.

Honest downside framing

What breaks this thesis? Explicit failure modes. When market regimes shift, what changes?

Methodology transparency

Every deliverable includes a methodology appendix. Code available on request. Reproducible.

Every engagement includes:

  • PDF report (15-30 pages) with full methodology + code availability
  • 1-hour analyst call to walk through findings + Q&A
  • Data package (CSV / Parquet) for your own rerun
  • Raw code / notebook on request (Python / R)
Who this is for

Buyers who value rigor over volume.

Family offices

Ablation-first second opinion on positions you're sizing up.

₹50K – ₹5L per report

Boutique PMS firms

Rigorous research to cite in client letters. 3-5 names per quarter.

₹1 – 3L per month

Multi-family offices

White-label research for HNI client briefings.

₹3 – 10L per month

Independent RIAs

Differentiated research without broker conflicts.

₹50K per report

AMC research desks

Supplementary methodology on names under coverage.

Case-by-case

Sample report

See the methodology in action.

What a sample report covers

  • Thesis (2-3 pages). The bull case, bear case, and why the market is mispricing one of them.
  • Ablation analysis. The alternative hypotheses we tested and ruled out, with supporting data.
  • Valuation framework. DCF + multiples + sensitivity tables. No black-box number.
  • Contrarian findings (3-5). Things consensus research missed, with supporting primary data.
  • Key risks. Regulatory, operational, management, with probability-weighted impact.
  • Methodology appendix. Every claim reproducible. Code + data sources on request.

Delivery

2-3 weeks

First draft after brief intake

20-40 pages

Typical length with appendix

PDF + raw data

Shared Drive, methodology appendix included

Request a sample report brief. We'll share scope + methodology on a 20-min call, and if there's fit, ship a first draft in 2-3 weeks.

Pricing

From ₹50K per report to enterprise white-label.

No self-serve checkout. Every engagement starts on a 20-min call. GST-compliant invoicing. Net 15 standard. Enterprise contracts signed directly with Koovis AI.

Get notified when WealthPilot Research opens for customers

No spam. One email when it ships.

FAQ

Common questions.

Are you offering investment advice?+

No. We publish research. Readers make their own investment decisions. WealthPilot is explicitly a research product, not an advisory, execution, or fund management service.

Are you SEBI-registered?+

No. We do not require SEBI registration because we do not offer investment advice, portfolio management, or execution. Our reports are research deliverables. Users are responsible for their own investment decisions.

How long does a report take?+

Standard deep-dive: 2-3 weeks from engagement. Expedited: 1 week (+₹25K surcharge). Monthly retainers deliver on the 15th of each month.

Can I see your methodology in full?+

Yes. Our validated 5-year OOS ablation paper publishes to arXiv + SSRN in 2026 (target journal: Pacific-Basin Finance Journal). Full methodology appendix in every report. Code available on request.

Do you trade the strategies you research?+

No. Research-only firm. No execution, no proprietary positions, no performance promises.

How do you differ from broker research?+

Three ways: (1) no sell-side conflicts, (2) ablation-first methodology — every claim tested against alternatives, (3) honest negative results published alongside positive ones.

Is this Indian equities only?+

Indian mid-cap + select large-cap coverage is our primary focus. Other markets available on request at bespoke pricing.